Finance professionals in Biotechnology

Experience: Vice President of Financial Planning Analysis · Vir Biotechnology, Inc.

Vice President of Financial Planning Analysis at Vir Biotechnology, Inc. since 2025. The profile describes building FP&A functions from the ground up over 20 years in biotech and biopharma. Other listed roles include Vice President of Finance And Operations at Element Science, Inc. (2023–2025), Vice President of Financial Planning Analysis at Element Science, Inc. (2023–2025), Head of Finance at CellFE Biotech / Tizona Therapeutics (2022–2023) and FP&A and Business Development Consulting at CellFE (2022–2023).

Experience: Corporate Controller · iBio, Inc.

Corporate Controller at iBio, Inc. since 2021. The highlights describe iBio, Inc. as a biotechnology research company. Other listed roles include Senior Director, Financial Reporting at Teva Pharmaceuticals (2000–2021), Senior Accountant at Sanofi (1998–2000) and Auditor at KPMG (1995–1998).

Experience: Senior Director, Finance and Controller · Ascidian Therapeutics

Senior Director, Finance and Controller at Ascidian Therapeutics since 2026. The profile describes a Chartered Accountant with over a decade of experience spanning Big 4 audit, accounting advisory and corporate controllership. Other listed roles include Director, Controller at Ascidian Therapeutics (2023–2026), Associate Director at CrossCountry Consulting (2022–2023), Managing Consultant at CrossCountry Consulting (2020–2021) and Senior Consultant at CrossCountry Consulting (2017–2019).

Experience: Sr. Director Financial Planning & Analysis · Intellia Therapeutics, Inc.

Sr. Director Financial Planning & Analysis at Intellia Therapeutics, Inc. since 2023. The profile describes 18 years in accounting, financial planning and strategic business analysis roles, plus over 7 years of engineering and operations experience in the biotech and polymer industries. Other listed roles include Sr. Director Finance, Operations Controller at Rubius Therapeutics (2022–2023), Finance Site Controller at Rubius Therapeutics (2019–2023) and Finance Director, Head of Finance for Biologics Operations at Takeda (2018–2019).

Experience: Senior Director, FP&A · Vir Biotechnology, Inc.

Former Senior Director, FP&A at Vir Biotechnology, Inc. (2023–2025). The profile describes over 25 years at the intersection of finance and biotechnology, specializing in strategic financial planning and analysis. Also Director, US Value and Access at Amgen since 2025. Other listed roles include Director, US Value and Access at Amgen (2021–2023), Director, Operations Finance at Amgen (2019–2021) and Director, Finance Transformation at Amgen (2018–2019).

Experience: Regional Chief Financial Officer Emerging & Partner Markets (Global Biopharma) · Biogen

Former Regional Chief Financial Officer Emerging & Partner Markets (Global Biopharma) at Biogen (2022–2026). The profile describes over 20 years of global finance experience, including leading multi-regional P&L management, capital deployment and financial transformation initiatives. Other listed roles include FP&A Director at Alnylam Pharmaceuticals (2026), Finance Director Emerging Markets Expansion Strategy at Biogen (2021–2022), Director of Global Trade Compliance & Risk Management at Biogen (2018–2021) and Director, Global PMO Biopharma Manufacturing Expansion at Biogen (2016–2018).

Experience: Director of Finance, US EU Head NASDAQ LEGN · Legend Biotech

Director of Finance, US EU Head NASDAQ LEGN at Legend Biotech since 2024. The profile describes leading FP&A and accounting across complex manufacturing operations, including launching three international sites, and building ERP systems, forecasting processes and management reporting. Other listed roles include Associate Director of Finance, US EU Head NASDAQ LEGN at Legend Biotech (2023–2024), Finance Manager, US Site Head NASDAQ LEGN at Legend Biotech (2021–2023), Senior Financial Analyst, Cell Therapy Pre IPO at Legend Biotech (2020–2021) and Financial Analyst at AMETEK PDS (2019–2020).

Experience: Senior Director Finance - Controller · Genetix Biotherapeutics

Senior Director Finance - Controller at Genetix Biotherapeutics since 2025. The profile describes over 20 years in accounting and finance, including driving timely financial closes, streamlining operations and ensuring SOX compliance. Other listed roles include Director - US Controller at Adaptimmune (2023–2025), Senior director of Finance and Commercial Controller at Novan, Inc. (2023), Director of Finance & Assistant Controller at Renovacor (2022–2023) and Associate Director - Accounting and Controls Lead - TBS at Takeda (2019–2022).

Experience: SVP Finance and Corporate Controller · Tessera Therapeutics

Former SVP Finance and Corporate Controller at Tessera Therapeutics (2021–2026). The profile describes a biotech finance leader who has executed three IPOs and builds the financial, operational and governance foundations that early-stage companies need. Other listed roles include VP Finance and Corporate Controller at Anika (2019–2021), SVP Finance and Operations at Spero Therapeutics (2015–2019), Executive Director Finance - Epizyme at Ipsen (2012–2015) and Senior Leadership and Global Finance at Biogen (2005–2012).

Experience: Senior Director of Accounting and Finance Business Processes · BlueRock Therapeutics

Senior Director of Accounting and Finance Business Processes at BlueRock Therapeutics since 2025. The profile describes 20+ years of life science accounting experience, including operations accounting, financial reporting and budget and forecast analysis. Also Director Of Accounting at BlueRock Therapeutics since 2020. Other listed roles include Associate Director, Accounting at CRISPR Therapeutics (2018–2020), Senior Manager, Accounting at CRISPR Therapeutics (2016–2018) and Manager of Accounting at FORUM Pharmaceuticals (2010–2016).